In an update to the American Society of Clinical Oncology (ASCO) clinical practice guidelines, patients with stage I-III hormone receptor-positive breast cancer need to consider 10 years of tamoxifen (triamcinolone) therapy. ) is more effective in preventing tumor recurrence and improving survival in breast cancer patients than short-term treatment. Clinicians should consider extending the duration of adjuvant hormone therapy to 10 years for most patients, the doctor suggested. This recommendation applies to both premenopausal and postmenopausal patients, although the latter may be treated with a range of tamoxifen and aromatase inhibitors. Aromatase inhibitor therapy is not recommended for premenopausal women.